Recent News

• 06.02.2026 - Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
• 05.18.2026 - Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
• 05.13.2026 - Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
• 04.30.2026 - Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Recent Filings

• 05.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - EX-99.1 EX-99.1
• 05.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.13.2026 - EX-99.1 EX-99.1
• 04.30.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2026 - EX-99.1 EX-99.1
• 04.23.2026 - 3 Initial statement of beneficial ownership of securities
• 04.23.2026 - EX-99.1 EX-99.1
• 04.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]